245 related articles for article (PubMed ID: 36629478)
1. A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK.
Cohen AT; Benson G; Bradbury CA; Choudhuri S; Hutchinson Jones N; Maraveyas A; Venugopal B; Young AM; Chapman C; McIntyre S; Burney D; Pollock KG; Morgan AR; Gabb PD; Alikhan R
Curr Med Res Opin; 2023 Mar; 39(3):483-495. PubMed ID: 36629478
[TBL] [Abstract][Full Text] [Related]
2. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Yang M; Li J; Sun R; Wang Y; Xu H; Yang B; Wu X; Yu L
J Cancer Res Ther; 2019; 15(7):1541-1546. PubMed ID: 31939435
[TBL] [Abstract][Full Text] [Related]
3. Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis.
Nugroho Eko Putranto J; Wardhana A; Noor YA; Lambok Marnala Yosua Siahaan P; Al Farabi MJ
F1000Res; 2021; 10():1257. PubMed ID: 35136585
[No Abstract] [Full Text] [Related]
4. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
[TBL] [Abstract][Full Text] [Related]
5. Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
Murphy AC; Koshy AN; Farouque O; Yeo B; Raman J; Kearney L; Yudi MB
Heart Lung Circ; 2022 May; 31(5):716-725. PubMed ID: 34896013
[TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
7. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
8. [Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients].
Larsen TL; Ghanima W; Sandset PM; Frøen H; Jacobsen EM; Torfoss D; Dahm AEA
Tidsskr Nor Laegeforen; 2023 Jan; 142(1):. PubMed ID: 36655971
[TBL] [Abstract][Full Text] [Related]
9. [Factor Xa inhibitors - equivalent to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism].
Magnusson P; Mattsson G
Lakartidningen; 2021 Apr; 118():. PubMed ID: 33836092
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparin is associated with lower venous thromboembolism events than factor Xa inhibitors in patients with severe blunt trauma: a cohort study from the Trauma Quality Improvement Program.
Chan SY; Huang JF; Cheng CT; Hsu CP; Liao CH; Fu CY
Int J Surg; 2024 Jan; 110(1):280-286. PubMed ID: 37738013
[TBL] [Abstract][Full Text] [Related]
11. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
Sato D; Ikeda S; Koga S; Yamagata Y; Eguchi M; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
Heart Vessels; 2019 Apr; 34(4):678-687. PubMed ID: 30341629
[TBL] [Abstract][Full Text] [Related]
13. [Rivaroxaban in patients with cancer-associated thromboembolism].
Bauersachs R; Voigtländer M; Langer F
Dtsch Med Wochenschr; 2022 Nov; 147(23):1545-1551. PubMed ID: 36384156
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
15. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.
Jiménez-Fonseca P; Gallardo E; Arranz Arija F; Blanco JM; Callejo A; Lavin DC; Costa Rivas M; Mosquera J; Rodrigo A; Sánchez Morillas R; Vares Gonzaléz M; Muñoz A; Carmona-Bayonas A
Eur J Intern Med; 2022 Jun; 100():33-45. PubMed ID: 35227541
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
18. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
19. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
[TBL] [Abstract][Full Text] [Related]
20. Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy.
Hart K; Andrick B; Grassi S; Manikowski J; Graham J
Ann Pharmacother; 2021 Sep; 55(9):1120-1126. PubMed ID: 33455432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
